Wellinks Raises $10M for Respiratory Care
Wellinks secured the first close of a $10M Series B to support virtual respiratory care and remote patient monitoring.
Remote patient monitoring is most useful when it helps spot problems before they become emergencies.
What happened
Wellinks secured the first close of a $10 million Series B. The company combines virtual chronic-care disease management with remote patient monitoring for respiratory conditions.
Its approach is focused on helping patients and care teams track health outside the clinic, especially for chronic respiratory diseases where symptoms can worsen over time and lead to costly interventions.
Why it matters
Chronic respiratory care is a practical healthtech market. Patients often need continuous support, but healthcare systems are not built around constant in-person monitoring.
Remote tools can help clinicians understand patient status earlier, intervene sooner and potentially reduce avoidable acute episodes. The difficult part is making the workflow clinically useful rather than adding more data noise.
The bigger picture
Digital health is moving away from broad wellness apps and toward condition-specific care infrastructure. Investors are more interested in platforms that fit real reimbursement, clinical workflows and patient needs.
Wellinks fits that direction. Its funding is not a mega-round, but it points to a continuing demand for tools that make chronic disease management more proactive, measurable and connected to care teams.